Sam Tetlow

Sam Tetlow has a diverse range of work experience in various companies and industries. Sam is the Founder & CEO of Grant Engine, a platform that helps secure grants from NIH, DoD, and other sources. Sam is also the President & Chairman of Amalgent Therapeutics, a clinical-stage pain management company. Additionally, they serve as the Chairman of PrimeNeuro, which develops software for early diagnosis and intervention in developmental disabilities. Sam has also held positions at RTP Capital Associates, Nike (as a product tester), BioFluidica Inc. (as Chairman of the Board and Chief Business Officer), EpiCypher (as Chief Executive Officer), ILS Genomics (as General Manager), Research Triangle Ventures (as a Partner), and Integrated Laboratory Systems (as Chief Business Officer). Sam has demonstrated expertise in strategy development, fundraising, corporate governance, and overall business management throughout their career.

Sam Tetlow obtained a Bachelor of Science degree in Aerospace Engineering from Worcester Polytechnic Institute. This educational achievement took place from 1989 to 1993. Later, Sam pursued an MBA degree with a focus on Venture Capital & Entrepreneurship from UNC Kenan-Flagler Business School, where they studied from 2001 to 2003. In addition to these formal educational experiences, Sam Tetlow also obtained a certification in Christie's Art Market Economics from Christie's in January 2021.